Evidence map›Paper›PMID 25100147›Full record

Trial reportPloS one2014

Urinary CD133+ extracellular vesicles are decreased in kidney transplanted patients with slow graft function and vascular damage.

Veronica Dimuccio, Andrea Ranghino, Loredana Praticò Barbato, Fabrizio Fop, Luigi Biancone, Giovanni Camussi, Benedetta Bussolati

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Identification of a serum and urine extracellular vesicle signature predicting renal outcome after kidney transplant.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Veronica DimuccioDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Andrea RanghinoDepartment of Medical Sciences, University of Torino, Torino, Italy.
Loredana Praticò BarbatoImmunogenetics and Transplant Biology Service, Città della Salute e della Scienza Hospital, Torino, Italy.
Fabrizio FopDivision of Nephrology, Dialysis and Transplantation, Città della Salute e della Scienza Hospital, Torino, Italy.
Luigi BianconeDepartment of Medical Sciences, University of Torino, Torino, Italy.
Giovanni CamussiDepartment of Medical Sciences, University of Torino, Torino, Italy.
Benedetta BussolatiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) present in the urine are mainly released from cells of the nephron and can therefore provide information on kidney function. We here evaluated the presence of vesicles expressing the progenitor marker CD133 in the urine of normal subjects and of patients undergoing renal transplant. We found that EV expressing CD133 were present in the urine of normal subjects, but not of patients with end stage renal disease. The first day after transplant, urinary CD133+ EVs were present at low levels, to increase thereafter (at day 7). Urinary CD133(+) EVs significantly increased in patients with slow graft function in respect to those with early graft function. In patients with a severe pre-transplant vascular damage of the graft, CD133(+) EVs did not increase at day 7. At variance, the levels of EVs expressing the renal exosomal marker CD24 did not vary in the urine of patients with end stage renal disease or in transplanted patients in respect to controls. Sorted CD133(+) EVs were found to express glomerular and proximal tubular markers. These data indicate that urinary CD133(+) EVs are continuously released during the homeostatic turnover of the nephron and may provide information on its function or regenerative potential.

Indexed as

Kidney GlomerulusKidney TransplantationKidney TubulesAC133 AntigenAdultAgedAntigens, CDCell-Derived MicroparticlesFemaleGlycoproteinsHumansKidney Failure, ChronicMaleMiddle AgedPeptidesTime FactorsAC133 AntigenAntigens, CDGlycoproteinsPeptidesPROM1 protein, human

Identifiers

PMID25100147
PMCPMC4123993
OpenAlexW2086272179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.